Integra Lifesciences Holdings Corp (NASDAQ:IART) major shareholder Richard E. Caruso sold 32,880 shares of Integra Lifesciences stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $53.68, for a total value of $1,764,998.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up $0.92 during mid-day trading on Monday, reaching $55.77. 384,321 shares of the company traded hands, compared to its average volume of 510,734. Integra Lifesciences Holdings Corp has a 12-month low of $40.51 and a 12-month high of $56.42. The firm has a market cap of $4,305.41, a P/E ratio of 68.01, a price-to-earnings-growth ratio of 1.69 and a beta of 0.65. The company has a quick ratio of 1.51, a current ratio of 2.36 and a debt-to-equity ratio of 1.85.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.08. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The firm had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. During the same quarter in the previous year, the company posted $0.52 EPS. The firm’s revenue for the quarter was up 44.2% on a year-over-year basis. sell-side analysts predict that Integra Lifesciences Holdings Corp will post 2.33 EPS for the current year.
Hedge funds have recently made changes to their positions in the stock. Orbimed Advisors LLC grew its holdings in Integra Lifesciences by 155.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after buying an additional 664,000 shares during the period. Jennison Associates LLC grew its holdings in Integra Lifesciences by 48.3% in the 3rd quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock valued at $52,232,000 after buying an additional 336,930 shares during the period. BlackRock Inc. grew its holdings in Integra Lifesciences by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,135,552 shares of the life sciences company’s stock valued at $389,367,000 after buying an additional 269,484 shares during the period. Broadfin Capital LLC grew its holdings in Integra Lifesciences by 321.1% in the 4th quarter. Broadfin Capital LLC now owns 330,600 shares of the life sciences company’s stock valued at $15,823,000 after buying an additional 252,100 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Integra Lifesciences by 92.4% in the 4th quarter. Renaissance Technologies LLC now owns 405,800 shares of the life sciences company’s stock valued at $19,422,000 after buying an additional 194,900 shares during the period. 90.93% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3258085/insider-selling-integra-lifesciences-holdings-corp-iart-major-shareholder-sells-32880-shares-of-stock.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.